PROGRESS AGAINST CANCER: A New Tool to Measure and Foster Innovation

We are at a pivotal point in the fight against cancer. New treatments and research building on another have transformed the lives of millions.

Cancer patients today are living longer than those diagnosed in earlier decades—and in some cases, beating cancer.¹

In fact, the chances a cancer patient will live five years or more increased by 39% across four major cancers between 1973 and 2005.¹

Every new cancer medicine reflects the cumulative nature of medical discovery. So do the policies that support it.

But it all begins with understanding where we are in the fight against different cancers—and how we got there.

That is why PACE (Patient Access to Cancer care Excellence), a Lilly Oncology initiative, created the PACE Continuous Innovation Indicators™ (PACE CII).

PACE CII uses Foster Progress, a scientific-based tool that allows policymakers, researchers, academics, and others to help health professionals better understand and describe the progress made against different types of cancer.

How it Works

At the heart of PACE CII is objective evidence; thousands of pieces of evidence-like pieces of a puzzle. This evidence is curated and collected from exploratory analyses from published sources such as clinical trial records and meta-analyses, observational studies and historical references.

Each piece of evidence is classified by disease stage and progression markers. Prognostic markers provide a treatment guide that forms a "VALUE MATRIX.

VALUE MATRIX

Dose-Detox
Dose-State

Example: A chemotherapy treatment shown to be effective for preventing a cancer from advancing—and a current standard of care—would be represented as a large, dark brown circle in this square.

To track cumulative research programs, the PACE Continuous Innovation Indicator™ employs a quantitative scoring mechanism—evidence scores of white—displayed in a generic graphic format.

Users can:

- Select the types of evidence they want to see.
- Adjust their own values.
- Add other parameters to achieve specific thresholds and goals.

E-SCORES PROVIDE A SCIENTIFICALLY-BASED ASSESSMENT OF THE LEVEL OF PROGRESS ACHIEVED BY EXISTING CANCER TREATMENTS.

With this information, users will:

- Quantify and visualize how continuous improvements continue to progress cancer care worldwide.
- See a vector understanding of the complete evolution of treatments and their effects.
- Monitor the value of programs against particular markers and specific state.
- Illustrate the potential impact of cancer care reform.

Learn more about PACE CII, please visit www.pacenetworkusa.com


The PACE Continuous Innovation Indicators™ is one of many initiatives underway by PACE, a global effort dedicated to encouraging public policies and investment that advance cancer care. Please note that data-driven conclusions and medical treatments inspired to the needs and qualities of individual patients and improve patient access to the most effective cancer medicines.

See terms and conditions at www.pacenetworkusa.com/privacy

Disclaimer: "PACE" and "PACE CII" refer to the PACE Continuous Innovation Indicators tools and services only. The PACE Continuous Innovation Indicators™ are not an endorsement or affirmation of PACE's views or recommendations. Their use is intended to improve public policy and investment in cancer care. Results may vary and are impacted by many factors, including: disease stage; socioeconomic status; access to healthcare; patient compliance; and other variables. Information is intended only for educational and informational purposes and should not be used in place of professional or medical advice.